<DOC>
	<DOC>NCT01809600</DOC>
	<brief_summary>This retrospective study is aimed at evaluating the safety and efficacy of rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or high-grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL.</brief_summary>
	<brief_title>Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults</brief_title>
	<detailed_description>Inclusion criteria 1. pathologically confirmed BL or BL-U by World Health Organization 2008 criteria 2. age &gt;20 yrs 3. received rituximab+chemotherapy as first-line treatment 4. with measurable or evaluable lesion 5. with complete set of clinical and laboratory data for the analysis</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1. pathologically confirmed Burkitt's lymphoma (BL) or High grade Bcell lymphoma, unclassifiable, with features intermediate between diffuse large Bcell lymphoma and BL (BLU) by WHO 2008 criteria 2. age &gt;20 yrs 3. received rituximab+chemotherapy as firstline treatment 4. with measurable or evaluable lesion 1. patients with BL or BLU previously treated with rituximab</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>